|
MC-1 Acute Clinical Trials
Medicure has completed three acute studies of MC-1;
Based on the results of the Phase III MEND-CABG 2 study, the Company does not plan on submitting an application for MC-1 marketing approval to the U.S. Food and Drug Administration for an acute indication at this time.
|
